

Synthetic Human Octreotide

Catalog No.:	PA1195
Quantity:	1 mg
Background:	Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. It inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone.
Species:	Human
Source:	Synthetic
Format:	State: Sterile Filtered White lyophilized (freeze-dried) powder. Purity: >98% pure as determined by RP-HPLC Buffer System: Octreotide was lyophilized from a concentrated (1.0 mg/ml) solution with no additives. Reconstitution: It is recommended to reconstitute the lyophilized Octreotide in sterile 18MΩ-cm H ₂ O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
Description:	Synthetic Human Octreotide is a single, non-glycosylated, polypeptide chain containing 8 amino acids, having a molecular formula of C ₄₉ H ₆₆ N ₁₀ O ₁₀ S ₂ . Octreotide is purified by proprietary chromatographic techniques. AA Sequence: H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol. Molecular weight: 1019.26 Dalton
Storage:	Lyophilized Octreotide although stable at room temperature, should be stored desiccated below 0°C. Reconstituted Octreotide is best stored refrigerated at 4°C. Please avoid freeze-thaw cycles.
General Readings:	<ol style="list-style-type: none">1. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis. <i>Hepatogastroenterology</i> 2007 Jan-Feb;54(73):250-32. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. <i>Hepatogastroenterology</i> 2007 Jan-Feb;54(73):195-2003. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. <i>J Nucl Med</i> 2007 Apr;48(4):508-184. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. <i>Gastroenterology</i> 2007 Mar;132(3):1104-165. Administration of octreotide for management of postoperative high-flow chylothorax. <i>Ann Vasc Surg</i> 2007 Jan;21(1):90-26. Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk

patients on anticoagulation therapy. Gut 2007 Mar;56(3):447